Back

DPP-4 inhibitors and SGLT2 inhibitors - A mechanism for the future?

28 August 2017 (13:10 - 13:20)
Organised by:
Congress Presentation Part of: Considerations for cardiologists: further insights into treatment options for patients with type 2 diabetes and cardiovascular disease Antiarrhythmic drugs ESC Premium Access ESC Congress 2017

About the speaker

Photo
Associate Professor David Cherney

Toronto (Canada)

6 More presentations in this session

Presentation thumbnail
Opening remarks - Considerations for cardiologists: further insights into treatment options for patients with type 2 diabetes and cardiovascular disease.
Professor S. Del Prato (Pisa, IT)
Presentation thumbnail
Why control glycemia?
Professor L. Leiter (Toronto, CA)
Presentation thumbnail
Clarifying the role for DPP-4 inhibitors in the treatment of patients with type 2 diabetes at risk of heart failure.
Professor D. McGuire (Dallas, US)
Presentation thumbnail
Q&A - Considerations for cardiologists: further insights into treatment options for patients with type 2 diabetes and cardiovascular disease.
Professor S. Del Prato (Pisa, IT)
Presentation thumbnail
Clinical considerations - A perspective across specialties.
Professor S. Del Prato (Pisa, IT) Professor D. McGuire (Dallas, US) Professor L. Leiter (Toronto, CA) Associate Professor D. Cherney (Toronto, CA)

Access the full session

Session thumbnail
Considerations for cardiologists: further insights into treatment options for patients with type 2 diabetes and cardiovascular disease

The Event

Event poster

ESC Congress 2017

28 August 2017 13:10 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources